Thymidine Kinase (TK1)

Thymidine kinase 1 (TK1), a special kinase that catalyzes thymidine (TdR) to 1-phosphothymidylate (TMP), is an essential precursor for DNA synthesis in cancerous cells.

1. TK1 is a cell cycle-dependent enzyme that mainly exists in the cytoplasm. When a large number of proliferating cells appear in the body, the level of TK-1 increases ly. Once canceration occurs, along with the proliferation of tumor cells, the activity and content of TK-1 will increase, which can exceed the normal level by 20-100 times.

2. TK1 (cytoplasmic thymidine kinase 1) is an internationally recognized marker of abnormal cell proliferation. It can detect the level of thymidine kinase 1 (STK1) in serum, dynamically understand the proliferation activity information of cancer cells in vivo, and evaluate the therapeutic effect of tumors. , an earlier predictor of tumor recurrence risk. Mainly used for: evaluating the effect of surgery, monitoring the effect of chemotherapy, predicting the risk of recurrence, and judging tumor prognosis, etc.

3. The application of TK1 to evaluate the effect of surgery. Scope of application: tumor surgery of various parts. Recommended monitoring points: 3 days or the same day before surgery, 7 days after surgery; before discharge, or 30 days after surgery, and before starting other treatments.


EXPLANATION OF THE TEST


TK1 is a cell cycle-dependent enzyme, mainly present in the cytoplasm. When a large number of proliferating cells appear in the body, the level of TK-1 increases ly. Once canceration occurs, along with the proliferation of tumor cells, the activity and content of TK-1 will increase, which can exceed the normal level by 20-100 times.

TK1 (cytoplasmic thymidine kinase 1) is an internationally recognized marker of abnormal cell proliferation. It can detect the level of thymidine kinase 1 (STK1) in serum, dynamically understand the proliferation activity information of cancer cells in vivo, evaluate the therapeutic effect of tumors, and more. early predictor of tumor recurrence risk. Mainly used for: evaluating the effect of surgery, monitoring the effect of chemotherapy, predicting the risk of recurrence, and judging tumor prognosis, etc.

Application of TK1 to assess surgical outcomes. Scope of application: tumor surgery of various parts. Recommended monitoring points: 3 days or the same day before surgery, 7 days after surgery; before discharge, or 30 days after surgery, and before starting other treatments.

Other Kind of Reagents we can provide:

Zecen Biotech CO., LTD., founded in 2011, is a leading Chinese diagnostics manufacturer specializing in in-vitro diagnostics devices and reagents. Zecen focus on the Chemiluminescent immunoassay (CLIA) field. With all products CE marked, our market presence currently spreads from across China to other countries including India, Switzerland, Russia etc., Zecen is expanding its footprint to become a global brand.

Zecen is the only enterprise with independent intellectual property rights in the entire chemiluminescence industry chain in China, including reagent, instrument, magnetic microbead, and reagent raw material. Our current products include more than 100 assays, from thyroid, inflammation, diabetes, tumer markers, immune disorders, hormones to cardiac markers. Our ever-expanding test menu helps our customers and collaborators keep up with the demands of healthcare sector. Zecen is striving for innovation and perfection to deliver the best products to the customers.

As a manufacturer, Zecen provide the OEM, ODM and other customized service of all products. We have the core R&D centers and innovative ability to lay a solid foundation for developing the broadest range of CLIA analyzers and test menu. High-quality sales and after-sales links provide the more intimate service. The patent and CE certification give us the confident sending all over the world, and more than 50 companys in the requiement of customized and have a long term coorperation with Zecen.